Plugging Up the Injured Spinal Cord

After spending the early 1970s studying regeneration in the Xenopus frog tadpole's optic nerve, Paul J. Reier began to ponder how mammalian spinal cord injuries (SCIs) might heal. Eventually, the junior professor at the University of Maryland School of Medicine chose to enter an emerging field: fetal cell transplantation into the spinal cord. A colleague called the career move crazy--a judgment that Reier now admits wasn't totally unwarranted. "The spinal cord injury field was clouded by pessimi

Written byDouglas Steinberg
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Fast-forward two decades: Reier, now a neuroscience professor at the University of Florida College of Medicine in Gainesville, is helping oversee a pioneering clinical trial in which eight SCI patients have received transplants of spinal cord tissue from human fetuses. Papers about the trial have just been published.1,2 In another trial, five SCI patients have received cord tissue from pig fetuses. In animal studies, many labs are treating SCI models with various cell types, ranging from workaday fibroblasts to sexy stem cells. Researchers regularly report that crippled animals regain some degree of function. Alan Tessler, a neurobiology and anatomy professor at Philadelphia's MCP Hahnemann Univer-sity, says he senses "tremendous optimism" in the field.

What has happened in 20 years? At least two landmark studies helped dispel researchers' pessimism. In 1980, researchers learned that mammalian central nervous system neurons, long considered inert, could grow if placed beside axon bundles grafted from ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies